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KEY POINTS

INTRODUCTION
When considering the financial sustainability of
neuromodulation for pain, one needs to consider
the varying costs involved with this therapy. These
can include costs leading up to neuromodulation
versus costs after neuromodulation is instituted;
comparisons between different types of neuromodulation; comparisons between neuromodulation
and conventional therapy; and comparisons between neuromodulation and other invasive modalities, such as spinal decompression with or
without fusion. In addition, any consideration of
cost also needs to take quality into account.
Even if a therapy is expensive, it is considered
cost-effective if it leads to significant increase in
quality of life and economic productivity of the patient. This review considers these questions,
methodologies used to assess them, and variations between different health delivery systems.

METHODOLOGY
Early studies tended to examine costs before an
intervention and compare them with costs after
an intervention. If the costs increase significantly,
the intervention will not seem (on the surface) to
be cost-effective. However, even if the costs of
health care use decreased after the intervention,

it is often unclear whether the costs would have
gone down anyway because of the natural history
of the disease decreasing in severity over time
(regression to the mean). Patients are more likely
to seek an intervention when their symptoms are
at their worst.
The simplest way of looking at costeffectiveness seems to be to examine costs of
care within the structure of prospective, randomized controlled trials, but these may not reflect
real life situations, because patients in clinical trials
tend to receive more attention and care. They have
avenues to reach research coordinators and clinicians, which can obviate expensive emergency
department (ED) visits and imaging. Therefore,
matched cohorts of patients where one group undergoes an intervention, and another similar group
does not are often considered more representative
of real life. This accounts for the natural history of
the disease condition. However, there are often
questions about whether the groups are
adequately matched. There could be reasons
that one group underwent the intervention, and
the other did not that are not reflected in
commonly used matched characteristics that are
easily captured, such as age, pain severity, race,
socioeconomic class, or International Classification of Diseases-10 code. It could even be that
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 Neuromodulation, especially spinal cord stimulation, has significant evidence suggesting that it is
more cost effective than continued medical management and traditional spine surgery.
 Many studies of cost effectiveness have limited applicability due to assumptions made in their
development, differences in health care systems and shifting technologies and costs over time.
 There is a need for prospective registries in neuromodulation and alternative therapies that include
analysis of cost effectiveness.
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the drive to seek the intervention or choose one
intervention over another could positively influence outcome.
An additional issue is that costs vary among
stakeholders.1 Private insurers consider the cost
of medical care, but governmental insurers may
also consider loss of taxpayer revenue from
inability to work and nonmedical costs, such as
need for increased social support. Employers
want their employees to return to work and not
draw disability payments. Patients consider costs
of insurance, copayments, and indirect costs,
such as time that caregivers may need to take
off work.
Even if the costs are higher for some period after
the intervention, it may be perceived as being
worthwhile for long-term improvement in quality
of life. Quality of life is generally expressed as
quality-adjusted life-years (QALYs), where a
QALY of 1 is equivalent to 1 year of perfect health
and a QALY of 0 is death.2 There are standardized
measures based on patient surveys, such as the
EQ-5D (EuroQol, Rotterdam, The Netherlands),
which are used to calculate QALYs.
QALYs are assigned to different outcomes. For
example, the patient who gets 5 years of benefit
from their spinal cord stimulator with significant
improvement in pain and function is going to
have a higher number of QALYs when compared
with the patient who lost benefit at a year and
then developed an infection, requiring explantation. Cost-effectiveness is generally expressed
as the incremental cost-effectiveness ratio
(ICER), defined as the difference in cost between
two treatments divided by the difference in effects
of the two treatments. Although the United States
Affordable Care Act prohibited decisions on health
insurance coverage based on cost per QALY, this
is not true in other countries. Most modern industrialized nations are willing to pay $50,000 to
$100,000 per QALY.
Decision trees and Markov models are developed to account for the probabilities of different
outcomes of differing values. Incidences of
different outcomes are varied as part of a sensitivity analysis to determine a threshold for willingness to pay (e.g., it might only make sense to
cover the procedure if the complication rate can
be brought lower than 5%).
Of course, the devil is in the details. There are
different results for the same intervention for
different indications. A therapy may not be costeffective at 1 year but can be at 3 or 5 years (or
vice versa), so duration of follow-up is paramount.
Costs for treatment and implants can vary widely
between countries: the average expense of a spinal cord stimulator system is CAN$21,595 in

Canada and $32,882 in the United States with
Medicare coverage.3 Caution should be applied
when referring to studies of cost-effectiveness
that are more than 10 years old because of
changes in pricing. In addition, other social issues
can lead to differences in cost: the United States is
an outlier in ED use. Imaging use and costs are
higher in the United States. Conversely, higher
rates of opioid use and abuse in the United States
lead to increased disability and death, so an
opioid-sparing modality, such as neuromodulation, may be particularly attractive.

SPINAL CORD STIMULATION
Most of the research done on cost-effectiveness
for neuromodulation has focused on spinal cord
stimulation (SCS), as nicely reviewed by Odonkor
and colleagues.3 Most analyses have been done
for back and leg pain after spinal surgery, although
there have also been some for complex regional
pain syndrome (CRPS), peripheral arterial disease,
refractory angina pectoris, neuropathic leg pain,
and chronic back and leg pain without prior spinal
surgery. In general, SCS was cost-effective when
compared with conventional therapy, even with
the higher implant and maintenance costs in the
United States. There is reduction in postoperative
use of physiotherapy, chiropractic treatment, massage therapy, injections, ED visits, imaging
studies, and pharmacotherapy in the SCS group.4
Despite the increased costs of rechargeable internal pulse generators (IPGs), they are generally
cost-effective if the life expectancy of a primary
cell is less than 4 years. The increased effectiveness and higher positive trial rate of some systems, such as those with 10-kHz stimulation
relative to those with paresthesia-inducing stimulation paradigms, may make them cost-effective
despite their increased cost.5 However, these findings are somewhat suspect in that the data used to
assess paresthesia-inducing stimulation were
from 9 years before6 with older technology.
Of note, there is evidence that delaying SCS
therapy with nonoperative options tended to lead
to decreased cost-effectiveness in addition to
decreased efficacy. Patients with longer preimplant histories of pain had higher opioid use, and
more frequent office visits and hospitalizations.
By examining insurance company data from
2000 to 2012 using the Truven Reuters MarketScan database (Truven Health Analytics, Ann Arbor, MI), Farber and colleagues7 were able to
identify 122,827 patients with failed back surgery
syndrome with at least a year of continuous data.
Truven data include inpatient and outpatient
claims from 200 million patients with employer-
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Fig. 1. Cost trends following SCS implantation for failed back surgery syndrome. (Farber SH, Han JL, Elsamadicy
AA, et al. Long-term cost utility of spinal cord stimulation in patients with failed back surgery syndrome. Pain
Phys 2017;20(6):E797-E805).7

based health insurance, Medicare, and Medicaid.
About 4% of patients who had chronic pain after
lumbar spinal surgery went on to have SCS systems implanted. Although the nature of the database precluded analysis of pain control and
patient satisfaction, there was significant reduction in costs after SCS implantation, generally
because of decreased health care use. The costs
before implant were more than double in the subgroup who underwent SCS when compared with
the conventional medical management (CMM)
group, suggesting that they had more disabling
pain that led to higher health care use. However,
even at 1 year, the SCS group had much lower
health care expenditures. These differences were
maintained at 9 years after SCS implantation
(Fig. 1).8 It is unclear how many patients in the
CMM group had expert care from pain physicians,
while it is reasonable to assume that most, if not
all, of those in the SCS patient group did. Therefore, it is difficult to parse whether the decreased
costs associated with SCS were caused by more
expert care from pain medicine physicians as
opposed to the procedure itself.
Often the alternative to SCS is not CMM but
repeat spinal surgery. In one systematic review,9
11 studies of cost-effectiveness in lumbar spinal
surgery were found to be of adequate quality. At
a population level, surgeries for decompression

were cost-effective relative to CMM at 1 year,
but surgery for spondylolisthesis only became
cost-effective at 4 years. However, as other
studies have noted,10 there is wide variability in
costs and outcomes of lumbar spinal surgery.
The oft-cited trial by North and colleagues11
from 2005 prospectively randomized patients
with radicular symptoms after lumbar spinal surgery to either repeat spinal surgery or SCS. The
patients did not have a progressive neurologic
deficit and were not grossly unstable. SCS was superior in terms of opioid use and pain relief with
lower neurologic morbidity and had a lower crossover rate to the other treatment modality. Economic analysis, at least within the UK National
Health System, suggested that SCS confers an
additional 0.98 QALYs when compared with
repeat spinal surgery, for an ICER of £6392 per
QALY. Spine surgeons tend to argue against the
validity of these findings because of the small sample size in the trial (n 5 50) at a single center and
advances in the field since then, including better
understanding of sagittal balance and improved
surgical techniques. However, SCS has also
advanced, and now features more complex lead
design and different stimulation paradigms that
have led to better results.12,13 Although it may be
difficult to organize and fund an updated prospective study of SCS versus repeat spine surgery,
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there is a need for registries that would enable
cohort matching of such patients to update this
prior analysis.

DORSAL ROOT GANGLION STIMULATION
In the industry-funded ACCURATE study, dorsal
root ganglion (DRG) stimulation was compared
with SCS with paresthesia-inducing stimulation
paradigms in the treatment of CRPS types 1 and
2 of the lower extremities.14 Subsequent analysis
of the costs was based on MarketScan data,15
with the assumption that the costs were the
same for both technologies because they share a
CPT code. The 10-year estimated costs of DRG
stimulation ($153,992  $36,651) were higher
than those associated with SCS ($128,269 
$27,771) and CMM ($106,173  $27,005), mostly
based on an estimate that the IPG for a DRG system would last 3.5 years and the rechargeable IPG
for the SCS system would last 9 years. Clearly the
costs of DRG and SCS are higher than CMM in this
model, but the ICER was $34,695 per QALY
gained with DRG over CMM, whereas the ICER
of SCS compared with CMM was $22,084 per
QALY. The difference in cost between DRG and
SCS narrows because of the higher positive trial
rate and increased efficacy of DRG stimulation
versus SCS in the trial. When comparing DRG
with SCS, the ICER was $68,095 per QALY.
Thus, if cost is an issue and one considers willingness to pay as part of coverage decisions (ie,
outside the United States), DRG is only favored
over conventional SCS if one is willing to pay
more than $68,000 per QALY. A cutoff of
$50,000/QALY would favor SCS. Subsequent analyses with newer IPGs for DRG stimulation, with an
estimated life of 6.5 years, make DRG much more
cost-effective with an ICER of DRG versus SCS of
$30,452/QALY.
However, the loss of efficacy rate and complication rate for DRG were based on the 12-month outcomes of the ACCURATE trial and expert opinion.
Because this technology has not been available for
10 years, extrapolations were necessary. It was
assumed that efficacy would remain stable from
12 months to 10 years. Despite clear evidence
that many patients with CRPS improve over time
with CMM,16,17 costs in the CMM arm were
assumed to be stable for 10 years. Thus, even
though sensitivity analysis was carried out using
a Monte Carlo simulation with 10,000 trials, many
of the assumptions may make this analysis invalid.
There is also no comparison of DRG versus
paresthesia-free SCS stimulation paradigms.
With advances in technology, much of the data
may no longer be relevant.

PERIPHERAL NERVE STIMULATION
Peripheral nerve stimulation is an expanding field.
Although first described by Scribonius Largus with
Torpedo fish in 153 CE,18 the modern era of implants for peripheral nerve stimulation began with
Wall and Sweet19 in 1967. Since then, most iterations involved directly exposing the nerve, wrapping a paddle electrode around the nerve,18 and
connecting the lead to an IPG. There were significant issues with scarring around nerves preventing normal sliding, and the potential need to
cross joints to place an IPG. However, there are
multiple new options for stimulation that do not
involve IPGs and can be placed through a Touhy
needle under fluoroscopic or ultrasound guidance.20,21 The patient places a pad over a receiver
to transmit energy to the system at much lower
cost than an IPG. Because of the lack of an IPG,
there is little financial justification for performing
a trial before a permanent implant. Performing a
lead placement with an externalized wire as a trial
before implanting a permanent lead and receiver
as permanent system essentially doubles the
cost. In addition, because of concern about infection, the length of the trial and number of stimulation parameters that can be tried are limited.22
Insurers are generally still requiring trials because
of their lack of understanding of the finances. A
cost-effectiveness analysis using claims data is
sorely needed to rectify this situation.
Currently, the only available study on costeffectiveness of peripheral nerve stimulation is for
occipital nerve stimulation for cluster headache in
a French registry.23 Data for 3 months were extrapolated to 1 year with significant benefit versus CMM
before implant. The average extrapolated total cost
for 1 year was V1344 lower for the occipital nerve
stimulation strategy with a gain of 0.28 QALY,
resulting in an ICER of V4846/QALY. However,
costs related to health care use could have gone
down anyway because of regression to the mean.
Characteristics of the French health care system
may not be relevant to other countries.

DEEP BRAIN STIMULATION
The earliest examples of the use of deep brain stimulation in the 1950s were for pain.24 However, the
Food and Drug Administration withdrew approval
for deep brain stimulation for pain in 1989. In
response, Medtronic (Dublin, Ireland) sponsored
two prospective trials to examine its efficacy.
Although these trials were completed in 1993 and
1998, they were not reported until 2001, presumably because of the poor outcomes.25 In general,
only 20% of patients had positive results. The
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success rate could not be significantly improved by
improving patient selection.26 Thus, although the
Affordable Care Act prohibits coverage decisions
based on cost, one might surmise that the low success rate and high costs of this procedure has led to
lack of coverage for these patients, despite the lack
of more effective alternatives in a patient population for whom this is the last resort.

MOTOR CORTEX STIMULATION
Motor cortex stimulation (MCS) has been performed since 1988 for various types of unilateral
face and arm deafferentation pain, with varying results. Despite being supported by two prospective
randomized controlled trials,27,28 the efficacy in
reducing preoperative pain by greater than 40%
is generally thought to be about 50%.29 The costs
of the initial procedure are high, because a craniotomy is generally involved and most clinicians
perform an inpatient externalized trial before
committing the patient to a permanent system
with an IPG.
One way to increase the cost-effectiveness is to
increase the likelihood of a successful trial. MCS is
more effective for facial pain, phantom limb pain,
and CRPS, compared with poststroke pain or pain
associated with brachial plexus avulsion.28 Machine learning has been used to identify preoperative characteristics to increase the likelihood of a
positive response to 66%.30 However, many would
find it unpalatable to deny care based on gender,
which is the most important factor in this dataset
in predicting response, even more than response
to repetitive transcranial magnetic stimulation.
Zaghi and colleagues31 analyzed costeffectiveness of MCS versus repetitive transcranial
magnetic stimulation and transcranial direct current
stimulation. Costs were estimated based on time,
salary, rent, and hospitalization-related costs, but
the sources are not clear. Claims data were not
used. MCS was estimated at $42,000, which seems
low. ICERs were expressed as cost per unit of Visual
Analog Scale. Subsequent analysis has suggested
that improvements in quality of life are not wholly
dependent on reduction in numeric pain scores.32
Given the methodologic problems of this article, not
much can be said about the cost-effectiveness of
MCS, even though this study favored MCS.

SUMMARY
Analyses of cost-effectiveness are important in
driving coverage policies. Many types of neuromodulation have been found to be cost-effective
when compared with continued, ineffective therapy or other interventions. However, care needs

to be taken in looking at the assumptions used in
model development. Although most studies look
at 2-year outcomes, that may be insufficient for
accurate analyses of cost-effectiveness. With advances in technology leading to better positive trial
rates and efficacy, neuromodulation may become
even more cost-effective over time. Registries that
include patient-reported outcomes and financial
data are needed to generate matched cohort trials
that can more accurately compare outcomes and
help direct resources effectively.

CLINICS CARE POINTS

 Be cautious of the assumptions used in cost
analyses of medical or surgical interventions.
 View old data with out-of-date technology
with skepticism when trying to compare to
current practice.
 Consider how applicable a cost analysis is to
your medical practice environment.
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